IL285084A - Inositol phosphate compounds for use in increasing tissular perfusion - Google Patents

Inositol phosphate compounds for use in increasing tissular perfusion

Info

Publication number
IL285084A
IL285084A IL285084A IL28508421A IL285084A IL 285084 A IL285084 A IL 285084A IL 285084 A IL285084 A IL 285084A IL 28508421 A IL28508421 A IL 28508421A IL 285084 A IL285084 A IL 285084A
Authority
IL
Israel
Prior art keywords
phosphate compounds
inositol phosphate
tissue perfusion
increasing tissue
increasing
Prior art date
Application number
IL285084A
Other languages
English (en)
Hebrew (he)
Original Assignee
Sanifit Therapeutics S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanifit Therapeutics S A filed Critical Sanifit Therapeutics S A
Publication of IL285084A publication Critical patent/IL285084A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL285084A 2019-01-30 2021-07-22 Inositol phosphate compounds for use in increasing tissular perfusion IL285084A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19382061 2019-01-30
US201962913259P 2019-10-10 2019-10-10
PCT/ES2020/070070 WO2020157362A1 (en) 2019-01-30 2020-01-30 Inositol phosphate compounds for use in increasing tissular perfusion

Publications (1)

Publication Number Publication Date
IL285084A true IL285084A (en) 2021-09-30

Family

ID=69770927

Family Applications (1)

Application Number Title Priority Date Filing Date
IL285084A IL285084A (en) 2019-01-30 2021-07-22 Inositol phosphate compounds for use in increasing tissular perfusion

Country Status (11)

Country Link
US (2) US20220000889A1 (enExample)
EP (1) EP3917535A1 (enExample)
JP (2) JP2022521119A (enExample)
KR (1) KR20210148078A (enExample)
CN (1) CN113365636A (enExample)
AU (1) AU2020213713B2 (enExample)
BR (1) BR112021014897A2 (enExample)
CA (1) CA3130735A1 (enExample)
IL (1) IL285084A (enExample)
MX (1) MX2021008966A (enExample)
WO (1) WO2020157362A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3113377A1 (en) 2018-10-11 2020-04-16 Sanifit Therapeutics S.A. Inositol phosphates for the treatment of ectopic calcification
AU2021380963A1 (en) * 2020-11-20 2023-06-22 ETH Zürich Inositol hexakisphosphate analogues for treatment of calcification associated kidney diseases
WO2024047037A1 (en) 2022-08-30 2024-03-07 ETH Zürich Compositions for parenteral sustained release delivery of hydrophilic drugs

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
ES2124303T3 (es) 1992-03-25 1999-02-01 Depomed Inc Formas de dosificacion de farmacos orales de liberacion retardada a base de hidroxietilcelulosa.
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
AU3290397A (en) 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
WO1998055107A1 (en) 1997-06-06 1998-12-10 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
JP2003507430A (ja) * 1999-08-25 2003-02-25 ジーエムピー カンパニーズ，インコーポレーテッド 哺乳動物中で酸素運搬を向上する薬剤
WO2001024830A2 (en) * 1999-10-05 2001-04-12 Theramed, Inc. Incorporation of chemical substances into cells
HK1050135A1 (zh) 1999-11-02 2003-06-13 Depomed, Inc. 用於促进将药物给予胃的饭後模式药理学诱导
DE60123384T2 (de) 2000-02-04 2007-08-02 DepoMed, Inc., Menlo Park Dosierungsform des typs "hülle und kern" mit einer wirkstofffreisetzung, die sich der nullten ordnung annähert
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
AU2001281071A1 (en) * 2000-08-01 2002-02-13 Gmp Companies, Inc. Ammonium salts of hemoglobin allosteric effectors, and uses thereof
US6610702B2 (en) * 2000-08-01 2003-08-26 Gmp Oxycell, Inc. Ammonium salts of inositol hexaphosphate, and uses thereof
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
JP3678144B2 (ja) 2000-12-22 2005-08-03 ウシオ電機株式会社 フィルム回路基板の周辺露光装置
MXPA03011096A (es) 2001-05-29 2004-12-06 Depomed Dev Ltd Metodo para el tratamiento de la enfermedad de reflujo gastroesofagico y la saturacion acida nocturna.
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
ES2232302B1 (es) 2003-11-07 2006-08-01 Universitat De Les Illes Balears Myo-inositol hexafosfato para uso topico.
ES2288126B2 (es) 2006-06-01 2009-07-06 Universitat De Les Illes Balears Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis.
ES2332636B1 (es) 2008-08-06 2011-02-10 Universitat De Les Illes Balears Composicion de liquido de dialisis.
BR112014007405B1 (pt) 2011-09-29 2021-07-13 Eth Zurich Composto, mio-inositol-pentaquisfosfato-2-peg(400) e forma farmacêutica
EP2579036A1 (en) 2011-10-06 2013-04-10 Laboratorios Sanifit, S.L. Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200
ES2495666B1 (es) * 2013-03-15 2015-08-10 Laboratoris Sanifit, S.L. Uso de derivados con enlaces c-o-p en pacientes con fallo renal
JP6893037B2 (ja) 2015-12-11 2021-06-23 エーテーハー・チューリッヒＥＴＨ Ｚｕｒｉｃｈ Ｃ．ｄｉｆｆｉｃｉｌｅ感染のための４，６−ジ−（Ｏ−チオホスフェート）−イノシトール−１，２，３，５−テトラ−Ｏ−スルフェート
DK3386548T3 (da) * 2015-12-11 2021-05-25 Eth Zuerich Inositol-derivater til anvendelse i patologisk krystallisering

Also Published As

Publication number Publication date
CA3130735A1 (en) 2020-08-06
JP2024175025A (ja) 2024-12-17
JP2022521119A (ja) 2022-04-06
BR112021014897A2 (pt) 2021-09-28
WO2020157362A1 (en) 2020-08-06
MX2021008966A (es) 2021-11-04
KR20210148078A (ko) 2021-12-07
US20230248749A1 (en) 2023-08-10
EP3917535A1 (en) 2021-12-08
US20220000889A1 (en) 2022-01-06
AU2020213713B2 (en) 2025-08-21
AU2020213713A1 (en) 2021-07-22
CN113365636A (zh) 2021-09-07

Similar Documents

Publication Publication Date Title
EP3989793C0 (en) SURGICAL CONSOLE INTERFACE
EP3322361A4 (en) BONE POSITIONING LEADERSHIP
EP2814397A4 (en) SYSTEM FOR TESTING THE EFFECTS OF ABLATION THERAPY ON HEART TISSUE BY PHOTOACOUSTICS
EP3434312A4 (en) ELONGATED BODY FOR MEDICAL PURPOSES
IL285084A (en) Inositol phosphate compounds for use in increasing tissular perfusion
EP3813693C0 (en) MEDICAL INSTRUMENT FOR PERCUTANEOUS RELEASE PROCEDURES
JP1671730S (ja) 医療用加湿器用タブ用部品
EP4035608C0 (en) Medical instrument
DK3119911T3 (da) Forbindelser til anvendelse til behandling af alzheimers sygdom hos apoe4+/+ patienter
SG11202100109TA (en) Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents
EP3834750C0 (en) MEDICAL INSTRUMENT
DK3151851T3 (da) Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af komplement-medierede sygdomme hos patienter med c5-polymorfisme
PL3685781T3 (pl) Przyrząd do koagulacji tkanek
PL3768284T3 (pl) Kompozycje z fageliny entrecoccus do zastosowania w terapii
EA201790432A1 (ru) Зонды для визуализации белка хантингтина
MX2020003049A (es) Semaglutida en la terapia medica.
EP3708131C0 (en) CIRCULATION LINE FOR INTRACAVITICAL HYPERTHERMIC PERFUSION
EP3747479A4 (en) MEDICAL INSTRUMENT
DK3465214T3 (da) Fremgangsmåder til forudsigelse af terapeutisk fordel ved anti-cd19-terapi hos patienter
JP2020523063A5 (ja) 血液成分採取用カセット
IL280638A (en) Fat tissue treatment
EP3302223A4 (en) MEDICAL OPTICAL EXAMINATION INSTRUMENT
IL282041A (en) Egfr inhibitors for treating keratodermas
EP3887514A4 (en) Therapeutic gene editing for elane-associated disease
EP3834747A4 (en) MEDICAL INSTRUMENT